HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HGH Import Alert Grows From 4 Products To 32 In 8 Months

This article was originally published in The Rose Sheet

Executive Summary

An April 18 alert update about a Chinese firm distributing HGH-containing supplements follows the launch of the alert in September and an update in November about other firms in the country reported as shipping supplements tainted with the ingredient.

You may also be interested in...



Grassley’s Swing At Illegal Anabolic Steroid Use Unfairly Strikes DHEA – CRN

Legislation introduced in response to a report on steroid use in Major League Baseball that would put an age restriction on sales of performance-enhancing drugs and supplements - including DHEA - is a "misdirected attempt ... based on emotional rhetoric" to curb illegal anabolic steroid use, industry leaders say

Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing

Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.

US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs

FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS109212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel